Drug Sensitivity and Mutation Profiling

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Florida International University
Updated on 19 July 2021
tumor cells


This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.


The excised tumors or a biopsy will be interrogated for sensitivity or resistance to FDA-approved and/or available investigational agents. In addition, normal samples (blood or buccal swab) will be collected for genetic analysis of germline mutations and cancer predisposition markers. The timeframe between the sample acquisition and ex vivo DST results return will be approximately 5-10 working days. All drugs tested in the DST assay will be assigned a hybrid score reflecting the tumor's sensitivity and drug toxicity.

This is an observational study and not a treatment protocol. It will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas

Condition Hereditary Neoplastic Syndrome, Soft Tissue Sarcoma, Ewing's sarcoma, Rhabdoid Tumor, Childhood Sarcoma of Soft Tissue, Sarcoma (Pediatric), Nephroblastoma, bone sarcoma, Rhabdomyosarcoma, Sarcoma, Malignant neoplasm of kidney, Wilms' Tumor, Renal Cancer, Hereditary Cancer Syndromes, Osteosarcoma, Kidney Cancer
Clinical Study IdentifierNCT04956198
SponsorFlorida International University
Last Modified on19 July 2021


Yes No Not Sure

Inclusion Criteria

Patients aged 21 years or younger at the time of enrollment on this study of any gender, race, or ethnicity
Subjects with suspected or confirmed diagnosis of all types of sarcomas
Subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers)
Subjects are willing to have a blood draw or buccal swab done for the purposes of genetic testing
Subjects or their parents or legal guardians willing to sign informed consent
Subjects aged 7 to 17 willing to sign assent

Exclusion Criteria

Subjects who do not have malignant tissue available and accessible
The amount of excised malignant tissue is not sufficient for ex vivo drug testing and/or genetic profiling
Patients with other types of tumors and tumors that have a high (>90%) cure rate with safe standard therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note